. home.aspx



GSK launches PhIII programme for otilimab in RA

July 04, 2019 / Selina McKee

GSK has kicked off a Phase III clinical development programme testing otilimab in patients with moderate to severe rheumatoid arthritis (RA) who have had an inadequate response to disease modifying antirheumatic drugs (DMARD) or targeted therapies. The move follows a successful Phase II study with the investigational anti-granulocyte macrophage colony-stimulating factor (anti GM-CSF) monoclonal antibody last year. The data, said Dr Hal Barron, chief scientific officer and president of R&D at GSK, showed “encouraging clinical benefits” in patients treated with the drug. “The unique Phase III studies, designed in consultation with regulators, will help us understand how this potential new medicine could benefit appropriate patients living with rheumatoid arthritis.” The Phase III clinical programme (ContRAst) is the first in RA to include head-to-head comparisons of otilimab with current treatments across all pivotal studies. It compares the drug against two t...